GlassScriptPhysician profile
Paul F Simonelli
NPI 1013918424
$21,320.58
in general payments reported to CMS, 2019-2025
8 companies · $6,823 in 2025
The $6,823 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,760 · 2022: $6,799 · 2023: $2,883 · 2024: $56.03 · 2025: $6,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,463 · Travel and Lodging: $873 · Food and Beverage: $391 · Education: $36.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,462.50 |
| Travel and Lodging | $872.67 |
| Food and Beverage | $390.51 |
| Education | $36.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $6,822.62 | 2025 | |
| Gilead Sciences, INC. | $6,798.71 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $4,760.01 | 2019 | |
| Genentech, INC. | $2,883.21 | 2023 | |
| Merck Sharp & Dohme LLC | $36.18 | 2024 | Winrevair |
| Pulmonx Corporation | $19.85 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Simonelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.